Circulating Tumor DNA as Biomarkers for Cancer Detection
|
摘要
Detection of circulating tumor DNAs(ct DNAs) in cancer patients is an important component of cancer precision medicine ct DNAs. Compared to the traditional physical and biochemical methods, blood-based ct DNA detection offers a non-invasive and easily accessible way for cancer diagnosis, prognostic determination, and guidance for treatment. While studies on this topic are currently underway, clinical translation of ct DNA detection in various types of cancers has been attracting much attention, due to the great potential of ct DNA as blood-based biomarkers for early diagnosis and treatment of cancers. ct DNAs are detected and tracked primarily based on tumorrelated genetic and epigenetic alterations. In this article, we reviewed the available studies on ct DNA detection and described the representative methods. We also discussed the current understanding of ct DNAs in cancer patients and their availability as potential biomarkers for clinical purposes. Considering the progress made and challenges involved in accurate detection of specific cell-free nucleic acids, ct DNAs hold promise to serve as biomarkers for cancer patients, and further validation is needed prior to their broad clinical use.
Detection of circulating tumor DNAs(ct DNAs) in cancer patients is an important component of cancer precision medicine ct DNAs. Compared to the traditional physical and biochemical methods, blood-based ct DNA detection offers a non-invasive and easily accessible way for cancer diagnosis, prognostic determination, and guidance for treatment. While studies on this topic are currently underway, clinical translation of ct DNA detection in various types of cancers has been attracting much attention, due to the great potential of ct DNA as blood-based biomarkers for early diagnosis and treatment of cancers. ct DNAs are detected and tracked primarily based on tumorrelated genetic and epigenetic alterations. In this article, we reviewed the available studies on ct DNA detection and described the representative methods. We also discussed the current understanding of ct DNAs in cancer patients and their availability as potential biomarkers for clinical purposes. Considering the progress made and challenges involved in accurate detection of specific cell-free nucleic acids, ct DNAs hold promise to serve as biomarkers for cancer patients, and further validation is needed prior to their broad clinical use.
Detection of circulating tumor DNAs(ct DNAs) in cancer patients is an important component of cancer precision medicine ct DNAs. Compared to the traditional physical and biochemical methods, blood-based ct DNA detection offers a non-invasive and easily accessible way for cancer diagnosis, prognostic determination, and guidance for treatment. While studies on this topic are currently underway, clinical translation of ct DNA detection in various types of cancers has been attracting much attention, due to the great potential of ct DNA as blood-based biomarkers for early diagnosis and treatment of cancers. ct DNAs are detected and tracked primarily based on tumorrelated genetic and epigenetic alterations. In this article, we reviewed the available studies on ct DNA detection and described the representative methods. We also discussed the current understanding of ct DNAs in cancer patients and their availability as potential biomarkers for clinical purposes. Considering the progress made and challenges involved in accurate detection of specific cell-free nucleic acids, ct DNAs hold promise to serve as biomarkers for cancer patients, and further validation is needed prior to their broad clinical use.
引文
[1]Mc Guire S.World Cancer Report 2014.Geneva,Switzerland:World Health Organization,International Agency for Research on Cancer,WHO Press,2015.Adv Nutr 2016;7:418-9.
[2]Dainiak N.Inferences,risk modeling,and prediction of health effects of ionizing radiation.Health Phys 2016;110:271-3.
[3]Zhou DD,Hao JL,Guo KM,Lu CW,Liu XD.Sperm quality and DNA damage in men from Jilin Province,China,who are occupationally exposed to ionizing radiation.Genet Mol Res2016;15:gmr8078.
[4]Chaudhuri AA,Binkley MS,Osmundson EC,Alizadeh AA,Diehn M.Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA.Semin Radiat Oncol 2015;25:305-12.
[5]Martin NE,D’Amico AV.Progress and controversies:radiation therapy for prostate cancer.CA Cancer J Clin 2014;64:389-407.
[6]Mancebo SE,Wang SQ.Skin cancer:role of ultraviolet radiation in carcinogenesis.Rev Environ Health 2014;29:265-73.
[7]Ignatiadis M,Lee M,Jeffrey SS.Circulating tumor cells and circulating tumor DNA:challenges and opportunities on the path to clinical utility.Clin Cancer Res 2015;21:4786-800.
[8]Wang Y,Waters J,Leung ML,Unruh A,Roh W,Shi X,et al.Clonal evolution in breast cancer revealed by single nucleus genome sequencing.Nature 2014;512:155-60.
[9]Hiley C,Bruin ECD,Mcgranahan N,Swanton C.Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine.Genome Biol 2014;15:1-10.
[10]Crowley E,Di Nicolantonio F,Loupakis F,Bardelli A.Liquid biopsy:monitoring cancer-genetics in the blood.Nat Rev Clin Oncol 2013;10:472-84.
[11]Alix-Panabieres C,Pantel K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy.Cancer Discovery 2016;6:479-91.
[12]Diaz Jr LA,Bardelli A.Liquid biopsies:genotyping circulating tumor DNA.J Clin Oncol 2014;32:579-86.
[13]Leung F,Kulasingam V,Diamandis EP,Hoon DS,Kinzler K,Pantel K,et al.Circulating tumor DNA as a cancer biomarker:fact or fiction?Clin Chem 2016;62:1054-60.
[14]Warton K,Mahon KL,Samimi G.Methylated circulating tumor DNA in blood:power in cancer prognosis and response.Endocr Relat Cancer 2016;23:R157-71.
[15]Shivapurkar N,Gazdar A.DNA methylation based biomarkers in non-invasive cancer screening.Curr Mol Med 2010;10:123-32.
[16]Cairns P.Gene methylation and early detection of genitourinary cancer:the road ahead.Nat Rev Cancer 2007;7:531-43.
[17]Chimonidou M,Strati A,Tzitzira A,Sotiropoulou G,Malamos N,Georgoulias V,et al.DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells.Clin Chem 2011;57:1169-77.
[18]Dulaimi E,Hillinck J,Ibanez de Caceres I,Al-Saleem T,Cairns P.Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.Clin Cancer Res 2004;10:6189-93.
[19]Hendee WR,Edwards FM.Health effects of exposure to lowlevel ionizing radiation.Acta Radiol 1998;39:453-4.
[20]Morgan WF,Sowa MB.Non-targeted effects induced by ionizing radiation:mechanisms and potential impact on radiation induced health effects.Cancer Lett 2015;356:17-21.
[21]Cho SH,Krishnan S.Cancer nanotechnology:principles and applications in radiation oncology.Boca Raton,FL:CRC Press;2013.
[22]Dechet CB,Sebo T,Farrow G,Blute ML,Engen DE,Zincke H.Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults.J Urol 1999;162:1282-4.
[23]Al-Leswas D,O’Reilly DA,Poston GJ.Biopsy of solid liver tumors:adverse consequences.Hepatobiliary Pancreat Dis Int2008;7:325-7.
[24]Yang Y,Li L,Qu C,Liang S,Zeng B,Luo Z.Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions:a systematic review and metaanalysis.Sci Rep 2016;6:22978.
[25]Hompes D,Ruers T.Review:incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.Eur J Surg Oncol2011;37:737-46.
[26]Mazzucchelli R,Colanzi P,Pomante R,Muzzonigro G,Montironi R.Prostate tissue and serum markers.Adv Clin Pathol2000;4:111-20.
[27]Ruibal Morell A.CEA serum levels in non-neoplastic disease.Int J Biol Markers 1992;7:160-6.
[28]Sikaris KA.CA125-a test with a change of heart.Heart Lung Circ 2011;20:634-40.
[29]Heitzer E,Auer M,Ulz P,Geigl JB,Speicher MR.Circulating tumor cells and DNA as liquid biopsies.Genome Med2013;5:1-11.
[30]Schwarzenbach H,Hoon DS,Pantel K.Cell-free nucleic acids as biomarkers in cancer patients.Nat Rev Cancer 2011;11:426-37.
[31]Heitzer E,Ulz P,Geigl JB.Circulating tumor DNA as a liquid biopsy for cancer.Clin Chem 2015;61:112-23.
[32]Vickers KC,Palmisano BT,Shoucri BM,Shamburek RD,Remaley AT.Micro RNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.Nat Cell Biol 2011;13:423-33.
[33]Giovannetti E,van der Velde A,Funel N,Vasile E,Perrone V,Leon LG,et al.High-throughput micro RNA(mi RNAs)arrays unravel the prognostic role of Mi R-211 in pancreatic cancer.PLo S One 2012;7:e49145.
[34]Wang Y,Gu J,Roth JA,Hildebrandt MA,Lippman SM,Ye Y,et al.Pathway-based serum micro RNA profiling and survival in patients with advanced stage non-small cell lung cancer.Cancer Res 2013;73:4801-9.
[35]Bang C,Thum T.Exosomes:new players in cell-cell communication.Int J Biochem Cell Biol 2012;44:2060-4.
[36]Simpson RJ,Lim JW,Moritz RL,Mathivanan S.Exosomes:proteomic insights and diagnostic potential.Expert Rev Proteomics 2009;6:267-83.
[37]Thakur BK,Zhang H,Becker A,Matei I,Huang Y,Costa-Silva B,et al.Double-stranded DNA in exosomes:a novel biomarker in cancer detection.Cell Res 2014;24:766-9.
[38]Dienstmann R,Rodon J,Tabernero J.Optimal design of trials to demonstrate the utility of genomically-guided therapy:putting precision cancer medicine to the test.Mol Oncol 2015;9:940-50.
[39]Arnedos M,Vicier C,Loi S,Lefebvre C,Michiels S,Bonnefoi H,et al.Precision medicine for metastatic breast cancer-limitations and solutions.Nat Rev Clin Oncol 2015;12:693-704.
[40]Baccelli I,Schneeweiss A,Riethdorf S,Stenzinger A,Schillert A,Vogel V,et al.Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.Nat Biotechnol 2013;31:539-44.
[41]Heitzer E,Ulz P,Belic J,Gutschi S,Quehenberger F,Fischereder K,et al.Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.Genome Med 2013;5:30.
[42]Hodgkinson CL,Morrow CJ,Li Y,Metcalf RL,Rothwell DG,Trapani F,et al.Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.Nat Med2014;20:897-903.
[43]Alix-Panabieres C,Pantel K.Challenges in circulating tumour cell research.Nat Rev Cancer 2014;14:623-31.
[44]Ashworth TR.A case of cancer in which cells similar to those in the tumors were seen in the blood after death.Aust Med J1869;14:146-7.
[45]Krishnamurthy S.The emerging role of circulating tumor cells in breast cancer.Cancer Cytopathol 2012;120:161-6.
[46]Hu B,Rochefort H,Goldkorn A.Circulating tumor cells in prostate cancer.Cancers(Basel)2013;5:1676-90.
[47]Scho¨lch S,Bork U,Rahbari NN,Garc?′a S,Swiersy A,Betzler AM,et al.Circulating tumor cells of colorectal cancer.Cancer Cell Microenviron 2014;1:e323.
[48]Pantel K,Brakenhoff RH,Brandt B.Detection,clinical relevance and specific biological properties of disseminating tumour cells.Nat Rev Cancer 2008;8:329-40.
[49]Riethdorf S,Fritsche H,Muller V,Rau T,Schindlbeck C,Rack B,et al.Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer:a validation study of the cell search system.Clin Cancer Res 2007;13:920-8.
[50]Nagrath S,Sequist LV,Maheswaran S,Bell DW,Irimia D,Ulkus L,et al.Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature 2007;450:1235-9.
[51]Issadore D,Chung J,Shao H,Liong M,Ghazani AA,Castro CM,et al.Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector.Sci Transl Med 2012;4:141ra92.
[52]Karabacak NM,Spuhler PS,Fachin F,Lim EJ,Pai V,Ozkumur E,et al.Microfluidic,marker-free isolation of circulating tumor cells from blood samples.Nat Protoc 2014;9:694-710.
[53]Dawson SJ,Tsui DW,Murtaza M,Biggs H,Rueda OM,Chin SF,et al.Analysis of circulating tumor DNA to monitor metastatic breast cancer.N Engl J Med 2013;368:1199-209.
[54]Siravegna G,Bardelli A.Blood circulating tumor DNA for noninvasive genotyping of colon cancer patients.Mol Oncol2016;10:475-80.
[55]Mabert K,Cojoc M,Peitzsch C,Kurth I,Souchelnytskyi S,Dubrovska A.Cancer biomarker discovery:current status and future perspectives.Int J Radiat Biol 2014;90:659-77.
[56]Mandel P,Metais P.Les acides nucleiques du plasma sanguin chez l’homme.CR Acad Sci Paris 1948;142:241-3.
[57]Leon SA,Shapiro B,Sklaroff DM,Yaros MJ.Free DNA in the serum of cancer patients and the effect of therapy.Cancer Res1977;37:646-50.
[58]Stroun M,Anker P,Maurice P,Lyautey J,Lederrey C,Beljanski M.Neoplastic characteristics of the DNA found in the plasma of cancer patients.Oncology 1989;46:318-22.
[59]Vasioukhin V,Anker P,Maurice P,Lyautey J,Lederrey C,Stroun M.Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia.Br J Haematol 1994;86:774-9.
[60]Fujiwara K,Fujimoto N,Tabata M,Nishii K,Matsuo K,Hotta K,et al.Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.Clin Cancer Res 2005;11:1219-25.
[61]Hardy T,Zeybel M,Day CP,Dipper C,Masson S,Mc Pherson S,et al.Plasma DNA methylation:a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.Gut 2016.http://www.idf.org/gutjnl-2016-311526.
[62]Jovelet C,Ileana E,Le Deley MC,Motte N,Rosellini S,Romero A,et al.Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial.Clin Cancer Res 2016;22:2960-8.
[63]Cheng F,Su L,Qian C.Circulating tumor DNA:a promising biomarker in the liquid biopsy of cancer.Oncotarget2016;7:48832-41.
[64]Diehl F,Schmidt K,Choti MA,Romans K,Goodman S,Li M,et al.Circulating mutant DNA to assess tumor dynamics.Nat Med 2008;14:985-90.
[65]Sun K,Jiang P,Chan KC,Wong J,Cheng YK,Liang RH,et al.Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal,cancer,and transplantation assessments.Proc Natl Acad Sci U S A 2015;112:E5503-12.
[66]Jahr S,Hentze H,Englisch S,Hardt D,Fackelmayer FO,Hesch RD,et al.DNA fragments in the blood plasma of cancer patients:quantitations and evidence for their origin from apoptotic and necrotic cells.Cancer Res 2001;61:1659-65.
[67]Fleischhacker M,Schmidt B.Circulating nucleic acids(CNAs)and cancer-a survey.Biochim Biophys Acta2007;1775:181-232.
[68]Bettegowda C,Sausen M,Leary RJ,Kinde I,Wang Y,Agrawal N,et al.Detection of circulating tumor DNA in early-and latestage human malignancies.Sci Transl Med 2014;6:224ra24.
[69]Gold B,Cankovic M,Furtado LV,Meier F,Gocke CD.Do circulating tumor cells,exosomes,and circulating tumor nucleic acids have clinical utility?J Mol Diagn 2015;17:209-24.
[70]Jiang P,Chan CW,Chan KC,Cheng SH,Wong J,Wong VW,et al.Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients.Proc Natl Acad Sci U S A 2015;112:E1317-25.
[71]Huang Z,Hua D,Hu Y,Cheng Z,Zhou X,Xie Q,et al.Quantitation of plasma circulating DNA using quantitative PCRfor the detection of hepatocellular carcinoma.Pathol Oncol Res2012;18:271-6.
[72]Hoque MO,Feng Q,Toure P,Dem A,Critchlow CW,Hawes SE,et al.Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.J Clin Oncol2006;24:4262-9.
[73]Webb S.The cancer bloodhounds.Nat Biotechnol2016;34:1090-4.
[74]Ferlay J,Shin HR,Bray F,Forman D,Mathers C,Parkin DM.Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008.Int J Cancer 2010;127:2893-917.
[75]Shaw JA,Page K,Blighe K,Hava N,Guttery D,Ward B,et al.Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.Genome Res 2012;22:220-31.
[76]Shah SS,Ketterling RP,Goetz MP,Ingle JN,Reynolds CA,Perez EA,et al.Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.Hum Pathol 2010;41:103-6.
[77]Higgins MJ,Jelovac D,Barnathan E,Blair B,Slater S,Powers P,et al.Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.Clin Cancer Res 2012;18:3462-9.
[78]Gevensleben H,Garcia-Murillas I,Graeser MK,Schiavon G,Osin P,Parton M,et al.Noninvasive detection of HER2amplification with plasma DNA digital PCR.Clin Cancer Res2013;19:3276-84.
[79]Beaver JA,Jelovac D,Balukrishna S,Cochran RL,Croessmann S,Zabransky DJ,et al.Detection of cancer DNA in plasma of patients with early-stage breast cancer.Clin Cancer Res2014;20:2643-50.
[80]Chu D,Paoletti C,Gersch C,Van Den Berg DA,Zabransky DJ,Cochran RL,et al.ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients.Clin Cancer Res2016;22:993-9.
[81]De Mattos-Arruda L,Cortes J,Santarpia L,Vivancos A,Tabernero J,Reis-Filho JS,et al.Circulating tumour cells and cell-free DNA as tools for managing breast cancer.Nat Rev Clin Oncol 2013;10:377-89.
[82]Olsson E,Winter C,George A,Chen Y,Howlin J,Tang MH,et al.Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.EMBO Mol Med 2015;7:1034-47.
[83]Kamel AM,Teama S,Fawzy A,El Deftar M.Plasma DNAintegrity index as a potential molecular diagnostic marker for breast cancer.Tumour Biol 2016;37:7565-72.
[84]Madic J,Kiialainen A,Bidard FC,Birzele F,Ramey G,Leroy Q,et al.Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.Int J Cancer2015;136:2158-65.
[85]Liggett TE,Melnikov AA,Marks JR,Levenson VV.Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.Int J Cancer 2011;128:492-9.
[86]Fiegl H,Millinger S,Mueller-Holzner E,Marth C,Ensinger C,Berger A,et al.Circulating tumor-specific DNA:a marker for monitoring efficacy of adjuvant therapy in cancer patients.Cancer Res 2005;65:1141-5.
[87]Fu D,Ren C,Tan H,Wei J,Zhu Y,He C,et al.Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.Medicine(Baltimore)2015;94:e637.
[88]Wittenberger T,Sleigh S,Reisel D,Zikan M,Wahl B,AlunniFabbroni M,et al.DNA methylation markers for early detection of women’s cancer:promise and challenges.Epigenomics2014;6:311-27.
[89]Avraham A,Uhlmann R,Shperber A,Birnbaum M,Sandbank J,Sella A,et al.Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients.Int J Cancer 2012;131:E1166-672.
[90]Yamamoto N,Nakayama T,Kajita M,Miyake T,Iwamoto T,Kim SJ,et al.Detection of aberrant promoter methylation of GSTP1,RASSF1A,and RARbeta2 in serum DNA of patients with breast cancer by a newly established one-step methylationspecific PCR assay.Breast Cancer Res Treat 2012;132:165-73.
[91]Mirza S,Sharma G,Parshad R,Srivastava A,Gupta SD,Ralhan R.Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients.Ann Surg Oncol 2012;19:3107-15.
[92]Li Z,Guo XW,Tang LL,Peng LM,Chen M,Luo XP,et al.Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.Tumor Biol 2016;37:13111-9.
[93]Siegel R,Desantis C,Jemal A.Colorectal cancer statistics,2014.CA Cancer J Clin 2014;64:104-17.
[94]Diaz Jr LA,Williams RT,Wu J,Kinde I,Hecht JR,Berlin J,et al.The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.Nature 2012;486:537-40.
[95]Siravegna G,Mussolin B,Buscarino M,Corti G,Cassingena A,Crisafulli G,et al.Clonal evolution and resistance to EGFRblockade in the blood of colorectal cancer patients.Nat Med2015;21:827.
[96]Spindler KL,Pallisgaard N,Vogelius I,Jakobsen A.Quantitative cell-free DNA,KRAS,and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.Clin Cancer Res 2012;18:1177-85.
[97]Spindler KL,Sorensen MM,Pallisgaard N,Andersen RF,Havelund BM,Ploen J,et al.Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer:outcome and results of KRAS mutational analysis in plasma.Acta Oncol 2013;52:963-70.
[98]Wang JY,Hsieh JS,Chang MY,Huang TJ,Chen FM,Cheng TL,et al.Molecular detection of APC,K-ras,and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.World J Surg 2004;28:721-6.
[99]Tie J,Kinde I,Wang Y,Wong HL,Roebert J,Christie M,et al.Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.Ann Oncol 2015;26:1715-22.
[100]Kidess E,Heirich K,Wiggin M,Vysotskaia V,Visser BC,Marziali A,et al.Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel,highsensitivity multiplexed mutation detection platform.Oncotarget2015;6:2549-61.
[101]Misale S,Yaeger R,Hobor S,Scala E,Janakiraman M,Liska D,et al.Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.Nature 2012;486:532-6.
[102]Bardelli A,Corso S,Bertotti A,Hobor S,Valtorta E,Siravegna G,et al.Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.Cancer Discovery2013;3:658-73.
[103]Misale S,Arena S,Lamba S,Siravegna G,Lallo A,Hobor S,et al.Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.Sci Transl Med 2014;6:162ra54.
[104]Mohan S,Heitzer E,Ulz P,Lafer I,Lax S,Auer M,et al.Changes in colorectal carcinoma genomes under anti-EGFRtherapy identified by whole-genome plasma DNA sequencing.PLo S Genet 2014;10:e1004271.
[105]Johnson V,Volikos E,Halford SE,Eftekhar Sadat ET,Popat S,Talbot I,et al.Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome.Gut 2005;54:264-7.
[106]Ilyas M,Tomlinson IPM,Rowan A,Pignatelli M,Bodmer WF.b-Catenin mutations in cell lines established from human colorectal cancers.Proc Natl Acad Sci U S A 1997;94:10330-4.
[107]Guo J,Cagatay T,Zhou G,Chan CC,Blythe S,Suyama K,et al.Mutations in the human naked cuticle homolog NKD1 found in colorectal cancer alter Wnt/Dvl/beta-catenin signaling.PLo SOne 2009;4:1493-4.
[108]Powrozek T,Krawczyk P,Kucharczyk T,Milanowski J.Septin 9promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer:preliminary report.Med Oncol 2014;31:917.
[109]Pack SC,Kim HR,Lim SW,Kim HY,Ko JY,Lee KS,et al.Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer.Int J Colorectal Dis 2013;28:139-47.
[110]Grawenda AM,O’Neill E.Clinical utility of RASSF1Amethylation in human malignancies.Br J Cancer 2015;113:372-81.
[111]Zhang Z,Lee JC,Lin L,Olivas V,Au V,La Framboise T,et al.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Nat Genet 2012;44:852-60.
[112]Bai H,Wang Z,Chen K,Zhao J,Lee JJ,Wang S,et al.Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.J Clin Oncol 2012;30:3077-83.
[113]Akca H,Demiray A,Yaren A,Bir F,Koseler A,Iwakawa R,et al.Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.Cancer Genet2013;206:73-80.
[114]Leary RJ,Sausen M,Kinde I,Papadopoulos N,Carpten JD,Craig D,et al.Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.Sci Transl Med 2012;4:162ra54.
[115]Narayan A,Carriero NJ,Gettinger SN,Kluytenaar J,Kozak KR,Yock TI,et al.Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.Cancer Res 2012;72:3492-8.
[116]Vinayanuwattikun C,Sriuranpong V,Tanasanvimon S,Chantranuwat P,Mutirangura A.Epithelial-specific methylation marker:a potential plasma biomarker in advanced non-small cell lung cancer.J Thorac Oncol 2011;6:1818-25.
[117]Jiao L,Zhu J,Hassan MM,Evans DB,Abbruzzese JL,Li D.K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients:in relation to cigarette smoking.Pancreas 2007;34:55-62.
[118]He WS,Bishop KS.The potential use of cell-free-circulatingtumor DNA as a biomarker for prostate cancer.Expert Rev Mol Diagn 2016;16:839-52.
[119]Cherepanova AV,Tamkovich SN,Bryzgunova OE,Vlassov VV,Laktionov PP.Deoxyribonuclease activity and circulating DNAconcentration in blood plasma of patients with prostate tumors.Ann NY Acad Sci 2008;1137:218-21.
[120]Delgado PO,Alves BC,Gehrke Fde S,Kuniyoshi RK,Wroclavski ML,Del Giglio A,et al.Characterization of cellfree circulating DNA in plasma in patients with prostate cancer.Tumour Biol 2013;34:983-6.
[121]Kinde I,Bettegowda C,Wang Y,Wu J,Agrawal N,Shih Ie M,et al.Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.Sci Transl Med 2013;5:167ra4.
[122]Murtaza M,Dawson SJ,Tsui DW,Gale D,Forshew T,Piskorz AM,et al.Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.Nature 2013;497:108-12.
[123]Sikora K,Bedin C,Vicentini C,Malpeli G,D’Angelo E,Sperandio N,et al.Evaluation of cell-free DNA as a biomarker for pancreatic malignancies.Int J Biol Markers 2015;30:e136-41.
[124]Laird PW.The power and the promise of DNA methylation markers.Nat Rev Cancer 2003;3:253-66.
[125]Feinberg A.DNA methylation in cancer:three decades of discovery.Genome Med 2014;6:1-4.
[126]Jin H,Ma Y,Shen Q,Wang X.Circulating methylated DNA as biomarkers for cancer detection.methylation-from DNA,RNAand histones to diseases and treatment.Intech 2013:137-52.
[127]Miotto E,Sabbioni S,Veronese A,Calin GA,Gullini S,Liboni A,et al.Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.Cancer Res2004;64:8156-9.
[128]Grady WM,Rajput A,Lutterbaugh JD,Markowitz SD.Detection of aberrantly methylated h MLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.Cancer Res 2001;61:900-2.
[129]Zou HZ,Yu BM,Wang ZW,Sun JY,Cai H,Gao F,et al.Detection of aberrant p16 methylation in the serum of colorectal cancer patients.Clin Cancer Res 2002;8:188-91.
[130]Lecomte T,Berger A,Zinzindohoue F,Micard S,Landi B,Blons H,et al.Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.Int J Cancer 2002;100:542-8.
[131]Ebert MP,Model F,Mooney S,Hale K,Lograsso J,TonnesPriddy L,et al.Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.Gastroenterology 2006;131:1418-30.
[132]Lofton-Day C,Model F,Devos T,Tetzner R,Distler J,Schuster M,et al.DNA methylation biomarkers for blood-based colorectal cancer screening.Clin Chem 2008;54:414-23.
[133]Warren JD,Xiong W,Bunker AM,Vaughn CP,Furtado LV,Roberts WL,et al.Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.BMC Med 2011;9:133.
[134]De Vos T,Tetzner R,Model F,Weiss G,Schuster M,Distler J,et al.Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.Clin Chem 2009;55:1337-46.
[135]Silva J,Dominguez G,Gonzalez R,Garcia J,Corbacho C,Provencio M,et al.Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients.Br JCancer 1999;80:1262-4.
[136]Esteller M,Sanchez-Cespedes M,Rosell R,Sidransky D,Baylin SB,Herman JG.Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.Cancer Res 1999;59:67-70.
[137]El Messaoudi S,Rolet F,Mouliere F,Thierry AR.Circulating cell free DNA:preanalytical considerations.Clin Chim Acta2013;424:222-30.
[138]Wang WY,Barratt BJ,Clayton DG,Todd JA.Genome-wide association studies:theoretical and practical concerns.Nat Rev Genet 2005;6:109-18.
[139]Xu J,Mo Z,Ye D,Wang M,Liu F,Jin G,et al.Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4.Nat Genet2012;44:1231-5.
[140]Forshew T,Murtaza M,Parkinson C,Gale D,Tsui DWY,Kaper F,et al.Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.Sci Transl Med 2012;4:136ra68.
[141]Ashida A,Sakaizawa K,Mikoshiba A,Uhara H,Okuyama R.Quantitative analysis of the BRAF mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific Taq Man PCR.Int J Clin Oncol 2016;21:981-8.
[142]Hindson CM,Chevillet JR,Briggs HA,Gallichotte EN,Ruf IK,Hindson BJ,et al.Absolute quantification by droplet digital PCR versus analog real-time PCR.Nat Methods2013;10:1003-5.
[143]Newman AM,Bratman SV,To J,Wynne JF,Eclov NC,Modlin LA,et al.An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.Nat Med2014;20:548-54.
[144]Bratman SV,Newman AM,Alizadeh AA,Diehn M.Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.Expert Rev Mol Diagn 2015;15:715-9.
[145]Newman AM,Lovejoy AF,Klass DM,Kurtz DM,Chabon JJ,Scherer F,et al.Integrated digital error suppression for improved detection of circulating tumor DNA.Nat Biotechnol2016;34:547-55.
[146]Chan KC,Jiang P,Zheng YW,Liao GJ,Sun H,Wong J,et al.Cancer genome scanning in plasma:detection of tumor-associated copy number aberrations,single-nucleotide variants,and tumoral heterogeneity by massively parallel sequencing.Clin Chem 2013;59:211-24.
[147]Vogelstein B,Kinzler KW.Digital PCR.Proc Natl Acad Sci U S A1999;96:9236-41.
[148]Gray ES,Rizos H,Reid AL,Boyd SC,Pereira MR,Lo J,et al.Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.Oncotarget 2015;6:42008-18.
[149]Tsao SC,Weiss J,Hudson C,Christophi C,Cebon J,Behren A,et al.Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Sci Rep 2015;5:11198.
[150]Huang A,Zhang X,Zhou SL,Cao Y,Huang XW,Fan J,et al.Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity.J Cancer 2016;7:1907-14.
[151]Laurent-Puig P,Pekin D,Normand C,Kotsopoulos SK,Nizard P,Perez-Toralla K,et al.Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.Clin Cancer Res 2015;21:1087-97.
[152]Denis JA,Patroni A,Guillerm E,Pe′pin D,Benali-Furet N,Wechsler J,et al.Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.Mol Oncol 2016;10:1221-31.
[153]Mishima C,Kagara N,Matsui S,Tanei T,Naoi Y,Shimoda M,et al.Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients.Springerplus2015;4:635.
[154]Balgkouranidou I,Chimonidou M,Milaki G,Tsaroucha E,Kakolyris S,Georgoulias V,et al.SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.Clin Chem Lab Med 2016;54:1385-93.
[155]Wang J,Qin Y,Li B,Sun Z,Yang B.Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.Clin Biochem 2006;39:344-8.
[156]Feehery GR,Pradhan S.Method for enriching methylated Cp Gsequences.US Patent Application 2013;US8367331.
[157]Herman JG,Graff JR,Myo¨ha¨nen S,Nelkin BD,Baylin SB.Methylation-specific PCR:a novel PCR assay for methylation status of Cp G islands.Proc Natl Acad Sci U S A 1996;93:9821-6.
[158]Licchesi JD,Herman JG.Methylation-specific PCR.Methods Mol Biol 2009;507:305-23.
[159]Kimler B,Fackler MJ,Metheny T,Phillips T,Sukumar S,Fabian C.Consistency of quantitative multiplexed-methylation specific PCR(QM-MSP)performed on breast epithelial cells acquired by random periareolar fine needle aspiration(RPFNA)of women at high risk for development of breast cancer.Cancer Res 2007;67.
[160]Bailey VJ,Zhang Y,Keeley BP,Yin C,Pelosky KL,Brock M,et al.Single-tube analysis of DNA methylation with silica superparamagnetic beads.Clin Chem 2010;56:1022-5.
[161]Wong IH,Lo YM,Zhang J,Liew CT,Ng MH,Wong N,et al.Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.Cancer Res 1999;59:71-3.
[162]Eads CA,Danenberg KD,Kawakami K,Saltz LB,Blake C,Shibata D,et al.Methy Light:a high-throughput assay to measure DNA methylation.Nucl Acids Res 2000;28:E32.
[163]Bailey VJ,Keeley BP,Zhang Y,Ho YP,Easwaran H,Brock MV,et al.Enzymatic incorporation of multiple dyes for increased sensitivity in QD-FRET sensing for DNA methylation detection.Chem Bio Chem 2010;11:71-4.
[164]Guzzetta AA,Pisanic Ii TR,Sharma P,Yi JM,Stark A,Wang TH,et al.The promise of methylation on beads for cancer detection and treatment.Expert Rev Mol Diagn 2014;14:845-52.
[165]Fackler MJ,Lopez Bujanda Z,Umbricht C,Teo WW,Cho S,Zhang Z,et al.Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.Cancer Res 2014;74:2160-70.
[166]Li Y,Zhu J,Geng T,Ning L,Li Q,Ye M,et al.The DNAmethylome of human peripheral blood mononuclear cells.PLo SBiol 2010;8:549-52.
[167]Urich MA,Nery JR,Lister R,Schmitz RJ,Ecker JR.Methyl C-seq library preparation for base-resolution whole-genome bisulfite sequencing.Nat Protoc 2015;10:475-83.
[168]Smith ZD,Gu HC,Bock C,Gnirke A,Meissner A.Highthroughput bisulfite sequencing in mammalian genomes.Methods 2009;48:226-32.
[169]Serre D,Lee BH,Ting AH.MBD-isolated genome sequencing provides a high-throughput and comprehensive survey of DNAmethylation in the human genome.Nucl Acids Res2010;38:391-9.
[170]Clark C,Palta P,Joyce CJ,Scott C,Grundberg E,Deloukas P,et al.A comparison of the whole genome approach of Me DIP-Seq to the targeted approach of the infinium humanmethylation450 Bead Chipòfor methylome profiling.PLo S One 2012;7:e50233.
[171]Taiwo O,Wilson GA,Morris T,Seisenberger S,Reik W,Pearce D,et al.Methylome analysis using Me DIP-seq with low DNAconcentrations.Nat Protoc 2012;7:617-36.
[172]Chan KC,Jiang P,Chan CW,Sun K,Wong J,Hui EP,et al.Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing.Proc Natl Acad Sci U S A2013;110:18761-8.
[173]Wen L,Li J,Guo H,Liu X,Zheng S,Zhang D,et al.Genomescale detection of hypermethylated Cp G islands in circulating cell-free DNA of hepatocellular carcinoma patients.Cell Res2015;25:1250-64.
[174]Rand K,Qu W,Ho T,Clark SJ,Molloy P.Conversion-specific detection of DNA methylation using real-time polymerase chain reaction(Con Light-MSP)to avoid false positives.Methods2002;27:114-20.
[175]Ilie M,Hofman V,Long E,Bordone O,Selva E,Washetine K,et al.Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids,and their characterization in non-small cell lung carcinoma patients.What is the best blood substrate for personalized medicine?Ann Transl Med2014;2:107.
[176]Gormally E,Caboux E,Vineis P,Hainaut P.Circulating free DNA in plasma or serum as biomarker of carcinogenesis:practical aspects and biological significance.Mutat Res2007;635:105-17.
[177]Schwarzenbach H,Muller V,Milde-Langosch K,Steinbach B,Pantel K.Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease.Mol Biosyst 2011;7:2848-54.
[178]Park JL,Kim HJ,Choi BY,Lee HC,Jang HR,Song KS,et al.Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients.Oncol Lett 2012;3:921-6.
[179]Salvianti F,Pinzani P,Verderio P,Ciniselli CM,Massi D,De Giorgi V,et al.Multiparametric analysis of cell-free DNA in melanoma patients.PLo S One 2012;7:e49843.
[180]Ha TT,Huy NT,Murao LA,Lan NT,Thuy TT,Tuan HM,et al.Elevated levels of cell-free circulating DNA in patients with acute dengue virus infection.PLo S One 2011;6:e25969.
[181]Huang CH,Tsai MS,Hsu CY,Chen HW,Wang TD,Chang WT,et al.Circulating cell-free DNA levels correlate with postresuscitation survival rates in out-of-hospital cardiac arrest patients.Resuscitation 2012;83:213-8.
[182]Iriyama C,Tomita A,Hoshino H,Adachi-Shirahata M,Furukawa-Hibi Y,Yamada K,et al.Using peripheral blood circulating DNAs to detect Cp G global methylation status and genetic mutations in patients with myelodysplastic syndrome.Biochem Biophys Res Commun 2012;419:662-9.
[183]Kwee S,Song MA,Cheng I,Loo L,Tiirikainen M.Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer.Clin Transl Sci 2012;5:65-70.
[184]Klein CA.Parallel progression of primary tumours and metastases.Nat Rev Cancer 2009;9:302-12.
[185]Ma M,Zhu H,Zhang C,Sun X,Gao X,Chen G.‘‘Liquid biopsy”-ct DNA detection with great potential and challenges.Ann Transl Med 2015;3:235.
[186]Pan H,Chen L,Dogra S,Teh AL,Tan JH,Lim YI,et al.Measuring the methylome in clinical samples:improved processing of the infinium human methylation450 beadchip array.Epigenetics 2012;7:1173-87.
[187]Mack SC,Witt H,Piro RM,Gu L,Zuyderduyn S,Stutz AM,et al.Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.Nature 2014;506:445-50.
[188]Hudecova I.Digital PCR analysis of circulating nucleic acids.Clin Biochem 2015;48:948-56.
[189]Jansen M,Martens J,Helmijr J,Beaufort C,Van M,Krol N,et al.Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.Oncotarget 2016;7:43412-8.
[190]Souverijn JH.Multitarget stool DNA testing for colorectalcancer screening.N Engl J Med 2014;371:187.
[191]Church TR,Wandell M,Lofton-Day C,Mongin SJ,Burger M,Payne SR,et al.Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.Gut2014;63:317-25.
[192]Ilse P,Biesterfeld S,Pomjanski N,Wrobel C,Schramm M.Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.Cancer Genomics Proteomics 2014;11:251-8.
[193]Brown P.The Cobas(ò)EGFR mutation test v2 assay.Future Oncol 2016;12:451-2.
[194]Kopreski M,Benko F,Kwee C,Leitzel K,Eskander E,Lipton A,et al.Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.Br J Cancer 1997;76:1293.
[195]Yamada T,Nakamori S,Ohzato H,Oshima S,Aoki T,Higaki N,et al.Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma:correlation with clinicopathological features.Clin Cancer Res 1998;4:1527-32.
[196]Sanchez-Cespedes M,Monzo M,Rosell R,Pifarre A,Calvo R,Lopez-Cabrerizo MP,et al.Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients.Ann Oncol 1998;9:113-6.
[2]Dainiak N.Inferences,risk modeling,and prediction of health effects of ionizing radiation.Health Phys 2016;110:271-3.
[3]Zhou DD,Hao JL,Guo KM,Lu CW,Liu XD.Sperm quality and DNA damage in men from Jilin Province,China,who are occupationally exposed to ionizing radiation.Genet Mol Res2016;15:gmr8078.
[4]Chaudhuri AA,Binkley MS,Osmundson EC,Alizadeh AA,Diehn M.Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA.Semin Radiat Oncol 2015;25:305-12.
[5]Martin NE,D’Amico AV.Progress and controversies:radiation therapy for prostate cancer.CA Cancer J Clin 2014;64:389-407.
[6]Mancebo SE,Wang SQ.Skin cancer:role of ultraviolet radiation in carcinogenesis.Rev Environ Health 2014;29:265-73.
[7]Ignatiadis M,Lee M,Jeffrey SS.Circulating tumor cells and circulating tumor DNA:challenges and opportunities on the path to clinical utility.Clin Cancer Res 2015;21:4786-800.
[8]Wang Y,Waters J,Leung ML,Unruh A,Roh W,Shi X,et al.Clonal evolution in breast cancer revealed by single nucleus genome sequencing.Nature 2014;512:155-60.
[9]Hiley C,Bruin ECD,Mcgranahan N,Swanton C.Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine.Genome Biol 2014;15:1-10.
[10]Crowley E,Di Nicolantonio F,Loupakis F,Bardelli A.Liquid biopsy:monitoring cancer-genetics in the blood.Nat Rev Clin Oncol 2013;10:472-84.
[11]Alix-Panabieres C,Pantel K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy.Cancer Discovery 2016;6:479-91.
[12]Diaz Jr LA,Bardelli A.Liquid biopsies:genotyping circulating tumor DNA.J Clin Oncol 2014;32:579-86.
[13]Leung F,Kulasingam V,Diamandis EP,Hoon DS,Kinzler K,Pantel K,et al.Circulating tumor DNA as a cancer biomarker:fact or fiction?Clin Chem 2016;62:1054-60.
[14]Warton K,Mahon KL,Samimi G.Methylated circulating tumor DNA in blood:power in cancer prognosis and response.Endocr Relat Cancer 2016;23:R157-71.
[15]Shivapurkar N,Gazdar A.DNA methylation based biomarkers in non-invasive cancer screening.Curr Mol Med 2010;10:123-32.
[16]Cairns P.Gene methylation and early detection of genitourinary cancer:the road ahead.Nat Rev Cancer 2007;7:531-43.
[17]Chimonidou M,Strati A,Tzitzira A,Sotiropoulou G,Malamos N,Georgoulias V,et al.DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells.Clin Chem 2011;57:1169-77.
[18]Dulaimi E,Hillinck J,Ibanez de Caceres I,Al-Saleem T,Cairns P.Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.Clin Cancer Res 2004;10:6189-93.
[19]Hendee WR,Edwards FM.Health effects of exposure to lowlevel ionizing radiation.Acta Radiol 1998;39:453-4.
[20]Morgan WF,Sowa MB.Non-targeted effects induced by ionizing radiation:mechanisms and potential impact on radiation induced health effects.Cancer Lett 2015;356:17-21.
[21]Cho SH,Krishnan S.Cancer nanotechnology:principles and applications in radiation oncology.Boca Raton,FL:CRC Press;2013.
[22]Dechet CB,Sebo T,Farrow G,Blute ML,Engen DE,Zincke H.Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults.J Urol 1999;162:1282-4.
[23]Al-Leswas D,O’Reilly DA,Poston GJ.Biopsy of solid liver tumors:adverse consequences.Hepatobiliary Pancreat Dis Int2008;7:325-7.
[24]Yang Y,Li L,Qu C,Liang S,Zeng B,Luo Z.Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions:a systematic review and metaanalysis.Sci Rep 2016;6:22978.
[25]Hompes D,Ruers T.Review:incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.Eur J Surg Oncol2011;37:737-46.
[26]Mazzucchelli R,Colanzi P,Pomante R,Muzzonigro G,Montironi R.Prostate tissue and serum markers.Adv Clin Pathol2000;4:111-20.
[27]Ruibal Morell A.CEA serum levels in non-neoplastic disease.Int J Biol Markers 1992;7:160-6.
[28]Sikaris KA.CA125-a test with a change of heart.Heart Lung Circ 2011;20:634-40.
[29]Heitzer E,Auer M,Ulz P,Geigl JB,Speicher MR.Circulating tumor cells and DNA as liquid biopsies.Genome Med2013;5:1-11.
[30]Schwarzenbach H,Hoon DS,Pantel K.Cell-free nucleic acids as biomarkers in cancer patients.Nat Rev Cancer 2011;11:426-37.
[31]Heitzer E,Ulz P,Geigl JB.Circulating tumor DNA as a liquid biopsy for cancer.Clin Chem 2015;61:112-23.
[32]Vickers KC,Palmisano BT,Shoucri BM,Shamburek RD,Remaley AT.Micro RNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.Nat Cell Biol 2011;13:423-33.
[33]Giovannetti E,van der Velde A,Funel N,Vasile E,Perrone V,Leon LG,et al.High-throughput micro RNA(mi RNAs)arrays unravel the prognostic role of Mi R-211 in pancreatic cancer.PLo S One 2012;7:e49145.
[34]Wang Y,Gu J,Roth JA,Hildebrandt MA,Lippman SM,Ye Y,et al.Pathway-based serum micro RNA profiling and survival in patients with advanced stage non-small cell lung cancer.Cancer Res 2013;73:4801-9.
[35]Bang C,Thum T.Exosomes:new players in cell-cell communication.Int J Biochem Cell Biol 2012;44:2060-4.
[36]Simpson RJ,Lim JW,Moritz RL,Mathivanan S.Exosomes:proteomic insights and diagnostic potential.Expert Rev Proteomics 2009;6:267-83.
[37]Thakur BK,Zhang H,Becker A,Matei I,Huang Y,Costa-Silva B,et al.Double-stranded DNA in exosomes:a novel biomarker in cancer detection.Cell Res 2014;24:766-9.
[38]Dienstmann R,Rodon J,Tabernero J.Optimal design of trials to demonstrate the utility of genomically-guided therapy:putting precision cancer medicine to the test.Mol Oncol 2015;9:940-50.
[39]Arnedos M,Vicier C,Loi S,Lefebvre C,Michiels S,Bonnefoi H,et al.Precision medicine for metastatic breast cancer-limitations and solutions.Nat Rev Clin Oncol 2015;12:693-704.
[40]Baccelli I,Schneeweiss A,Riethdorf S,Stenzinger A,Schillert A,Vogel V,et al.Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.Nat Biotechnol 2013;31:539-44.
[41]Heitzer E,Ulz P,Belic J,Gutschi S,Quehenberger F,Fischereder K,et al.Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.Genome Med 2013;5:30.
[42]Hodgkinson CL,Morrow CJ,Li Y,Metcalf RL,Rothwell DG,Trapani F,et al.Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.Nat Med2014;20:897-903.
[43]Alix-Panabieres C,Pantel K.Challenges in circulating tumour cell research.Nat Rev Cancer 2014;14:623-31.
[44]Ashworth TR.A case of cancer in which cells similar to those in the tumors were seen in the blood after death.Aust Med J1869;14:146-7.
[45]Krishnamurthy S.The emerging role of circulating tumor cells in breast cancer.Cancer Cytopathol 2012;120:161-6.
[46]Hu B,Rochefort H,Goldkorn A.Circulating tumor cells in prostate cancer.Cancers(Basel)2013;5:1676-90.
[47]Scho¨lch S,Bork U,Rahbari NN,Garc?′a S,Swiersy A,Betzler AM,et al.Circulating tumor cells of colorectal cancer.Cancer Cell Microenviron 2014;1:e323.
[48]Pantel K,Brakenhoff RH,Brandt B.Detection,clinical relevance and specific biological properties of disseminating tumour cells.Nat Rev Cancer 2008;8:329-40.
[49]Riethdorf S,Fritsche H,Muller V,Rau T,Schindlbeck C,Rack B,et al.Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer:a validation study of the cell search system.Clin Cancer Res 2007;13:920-8.
[50]Nagrath S,Sequist LV,Maheswaran S,Bell DW,Irimia D,Ulkus L,et al.Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature 2007;450:1235-9.
[51]Issadore D,Chung J,Shao H,Liong M,Ghazani AA,Castro CM,et al.Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector.Sci Transl Med 2012;4:141ra92.
[52]Karabacak NM,Spuhler PS,Fachin F,Lim EJ,Pai V,Ozkumur E,et al.Microfluidic,marker-free isolation of circulating tumor cells from blood samples.Nat Protoc 2014;9:694-710.
[53]Dawson SJ,Tsui DW,Murtaza M,Biggs H,Rueda OM,Chin SF,et al.Analysis of circulating tumor DNA to monitor metastatic breast cancer.N Engl J Med 2013;368:1199-209.
[54]Siravegna G,Bardelli A.Blood circulating tumor DNA for noninvasive genotyping of colon cancer patients.Mol Oncol2016;10:475-80.
[55]Mabert K,Cojoc M,Peitzsch C,Kurth I,Souchelnytskyi S,Dubrovska A.Cancer biomarker discovery:current status and future perspectives.Int J Radiat Biol 2014;90:659-77.
[56]Mandel P,Metais P.Les acides nucleiques du plasma sanguin chez l’homme.CR Acad Sci Paris 1948;142:241-3.
[57]Leon SA,Shapiro B,Sklaroff DM,Yaros MJ.Free DNA in the serum of cancer patients and the effect of therapy.Cancer Res1977;37:646-50.
[58]Stroun M,Anker P,Maurice P,Lyautey J,Lederrey C,Beljanski M.Neoplastic characteristics of the DNA found in the plasma of cancer patients.Oncology 1989;46:318-22.
[59]Vasioukhin V,Anker P,Maurice P,Lyautey J,Lederrey C,Stroun M.Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia.Br J Haematol 1994;86:774-9.
[60]Fujiwara K,Fujimoto N,Tabata M,Nishii K,Matsuo K,Hotta K,et al.Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.Clin Cancer Res 2005;11:1219-25.
[61]Hardy T,Zeybel M,Day CP,Dipper C,Masson S,Mc Pherson S,et al.Plasma DNA methylation:a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.Gut 2016.http://www.idf.org/gutjnl-2016-311526.
[62]Jovelet C,Ileana E,Le Deley MC,Motte N,Rosellini S,Romero A,et al.Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial.Clin Cancer Res 2016;22:2960-8.
[63]Cheng F,Su L,Qian C.Circulating tumor DNA:a promising biomarker in the liquid biopsy of cancer.Oncotarget2016;7:48832-41.
[64]Diehl F,Schmidt K,Choti MA,Romans K,Goodman S,Li M,et al.Circulating mutant DNA to assess tumor dynamics.Nat Med 2008;14:985-90.
[65]Sun K,Jiang P,Chan KC,Wong J,Cheng YK,Liang RH,et al.Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal,cancer,and transplantation assessments.Proc Natl Acad Sci U S A 2015;112:E5503-12.
[66]Jahr S,Hentze H,Englisch S,Hardt D,Fackelmayer FO,Hesch RD,et al.DNA fragments in the blood plasma of cancer patients:quantitations and evidence for their origin from apoptotic and necrotic cells.Cancer Res 2001;61:1659-65.
[67]Fleischhacker M,Schmidt B.Circulating nucleic acids(CNAs)and cancer-a survey.Biochim Biophys Acta2007;1775:181-232.
[68]Bettegowda C,Sausen M,Leary RJ,Kinde I,Wang Y,Agrawal N,et al.Detection of circulating tumor DNA in early-and latestage human malignancies.Sci Transl Med 2014;6:224ra24.
[69]Gold B,Cankovic M,Furtado LV,Meier F,Gocke CD.Do circulating tumor cells,exosomes,and circulating tumor nucleic acids have clinical utility?J Mol Diagn 2015;17:209-24.
[70]Jiang P,Chan CW,Chan KC,Cheng SH,Wong J,Wong VW,et al.Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients.Proc Natl Acad Sci U S A 2015;112:E1317-25.
[71]Huang Z,Hua D,Hu Y,Cheng Z,Zhou X,Xie Q,et al.Quantitation of plasma circulating DNA using quantitative PCRfor the detection of hepatocellular carcinoma.Pathol Oncol Res2012;18:271-6.
[72]Hoque MO,Feng Q,Toure P,Dem A,Critchlow CW,Hawes SE,et al.Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.J Clin Oncol2006;24:4262-9.
[73]Webb S.The cancer bloodhounds.Nat Biotechnol2016;34:1090-4.
[74]Ferlay J,Shin HR,Bray F,Forman D,Mathers C,Parkin DM.Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008.Int J Cancer 2010;127:2893-917.
[75]Shaw JA,Page K,Blighe K,Hava N,Guttery D,Ward B,et al.Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.Genome Res 2012;22:220-31.
[76]Shah SS,Ketterling RP,Goetz MP,Ingle JN,Reynolds CA,Perez EA,et al.Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.Hum Pathol 2010;41:103-6.
[77]Higgins MJ,Jelovac D,Barnathan E,Blair B,Slater S,Powers P,et al.Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.Clin Cancer Res 2012;18:3462-9.
[78]Gevensleben H,Garcia-Murillas I,Graeser MK,Schiavon G,Osin P,Parton M,et al.Noninvasive detection of HER2amplification with plasma DNA digital PCR.Clin Cancer Res2013;19:3276-84.
[79]Beaver JA,Jelovac D,Balukrishna S,Cochran RL,Croessmann S,Zabransky DJ,et al.Detection of cancer DNA in plasma of patients with early-stage breast cancer.Clin Cancer Res2014;20:2643-50.
[80]Chu D,Paoletti C,Gersch C,Van Den Berg DA,Zabransky DJ,Cochran RL,et al.ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients.Clin Cancer Res2016;22:993-9.
[81]De Mattos-Arruda L,Cortes J,Santarpia L,Vivancos A,Tabernero J,Reis-Filho JS,et al.Circulating tumour cells and cell-free DNA as tools for managing breast cancer.Nat Rev Clin Oncol 2013;10:377-89.
[82]Olsson E,Winter C,George A,Chen Y,Howlin J,Tang MH,et al.Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.EMBO Mol Med 2015;7:1034-47.
[83]Kamel AM,Teama S,Fawzy A,El Deftar M.Plasma DNAintegrity index as a potential molecular diagnostic marker for breast cancer.Tumour Biol 2016;37:7565-72.
[84]Madic J,Kiialainen A,Bidard FC,Birzele F,Ramey G,Leroy Q,et al.Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.Int J Cancer2015;136:2158-65.
[85]Liggett TE,Melnikov AA,Marks JR,Levenson VV.Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.Int J Cancer 2011;128:492-9.
[86]Fiegl H,Millinger S,Mueller-Holzner E,Marth C,Ensinger C,Berger A,et al.Circulating tumor-specific DNA:a marker for monitoring efficacy of adjuvant therapy in cancer patients.Cancer Res 2005;65:1141-5.
[87]Fu D,Ren C,Tan H,Wei J,Zhu Y,He C,et al.Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.Medicine(Baltimore)2015;94:e637.
[88]Wittenberger T,Sleigh S,Reisel D,Zikan M,Wahl B,AlunniFabbroni M,et al.DNA methylation markers for early detection of women’s cancer:promise and challenges.Epigenomics2014;6:311-27.
[89]Avraham A,Uhlmann R,Shperber A,Birnbaum M,Sandbank J,Sella A,et al.Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients.Int J Cancer 2012;131:E1166-672.
[90]Yamamoto N,Nakayama T,Kajita M,Miyake T,Iwamoto T,Kim SJ,et al.Detection of aberrant promoter methylation of GSTP1,RASSF1A,and RARbeta2 in serum DNA of patients with breast cancer by a newly established one-step methylationspecific PCR assay.Breast Cancer Res Treat 2012;132:165-73.
[91]Mirza S,Sharma G,Parshad R,Srivastava A,Gupta SD,Ralhan R.Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients.Ann Surg Oncol 2012;19:3107-15.
[92]Li Z,Guo XW,Tang LL,Peng LM,Chen M,Luo XP,et al.Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.Tumor Biol 2016;37:13111-9.
[93]Siegel R,Desantis C,Jemal A.Colorectal cancer statistics,2014.CA Cancer J Clin 2014;64:104-17.
[94]Diaz Jr LA,Williams RT,Wu J,Kinde I,Hecht JR,Berlin J,et al.The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.Nature 2012;486:537-40.
[95]Siravegna G,Mussolin B,Buscarino M,Corti G,Cassingena A,Crisafulli G,et al.Clonal evolution and resistance to EGFRblockade in the blood of colorectal cancer patients.Nat Med2015;21:827.
[96]Spindler KL,Pallisgaard N,Vogelius I,Jakobsen A.Quantitative cell-free DNA,KRAS,and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.Clin Cancer Res 2012;18:1177-85.
[97]Spindler KL,Sorensen MM,Pallisgaard N,Andersen RF,Havelund BM,Ploen J,et al.Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer:outcome and results of KRAS mutational analysis in plasma.Acta Oncol 2013;52:963-70.
[98]Wang JY,Hsieh JS,Chang MY,Huang TJ,Chen FM,Cheng TL,et al.Molecular detection of APC,K-ras,and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.World J Surg 2004;28:721-6.
[99]Tie J,Kinde I,Wang Y,Wong HL,Roebert J,Christie M,et al.Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.Ann Oncol 2015;26:1715-22.
[100]Kidess E,Heirich K,Wiggin M,Vysotskaia V,Visser BC,Marziali A,et al.Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel,highsensitivity multiplexed mutation detection platform.Oncotarget2015;6:2549-61.
[101]Misale S,Yaeger R,Hobor S,Scala E,Janakiraman M,Liska D,et al.Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.Nature 2012;486:532-6.
[102]Bardelli A,Corso S,Bertotti A,Hobor S,Valtorta E,Siravegna G,et al.Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.Cancer Discovery2013;3:658-73.
[103]Misale S,Arena S,Lamba S,Siravegna G,Lallo A,Hobor S,et al.Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.Sci Transl Med 2014;6:162ra54.
[104]Mohan S,Heitzer E,Ulz P,Lafer I,Lax S,Auer M,et al.Changes in colorectal carcinoma genomes under anti-EGFRtherapy identified by whole-genome plasma DNA sequencing.PLo S Genet 2014;10:e1004271.
[105]Johnson V,Volikos E,Halford SE,Eftekhar Sadat ET,Popat S,Talbot I,et al.Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome.Gut 2005;54:264-7.
[106]Ilyas M,Tomlinson IPM,Rowan A,Pignatelli M,Bodmer WF.b-Catenin mutations in cell lines established from human colorectal cancers.Proc Natl Acad Sci U S A 1997;94:10330-4.
[107]Guo J,Cagatay T,Zhou G,Chan CC,Blythe S,Suyama K,et al.Mutations in the human naked cuticle homolog NKD1 found in colorectal cancer alter Wnt/Dvl/beta-catenin signaling.PLo SOne 2009;4:1493-4.
[108]Powrozek T,Krawczyk P,Kucharczyk T,Milanowski J.Septin 9promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer:preliminary report.Med Oncol 2014;31:917.
[109]Pack SC,Kim HR,Lim SW,Kim HY,Ko JY,Lee KS,et al.Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer.Int J Colorectal Dis 2013;28:139-47.
[110]Grawenda AM,O’Neill E.Clinical utility of RASSF1Amethylation in human malignancies.Br J Cancer 2015;113:372-81.
[111]Zhang Z,Lee JC,Lin L,Olivas V,Au V,La Framboise T,et al.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Nat Genet 2012;44:852-60.
[112]Bai H,Wang Z,Chen K,Zhao J,Lee JJ,Wang S,et al.Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.J Clin Oncol 2012;30:3077-83.
[113]Akca H,Demiray A,Yaren A,Bir F,Koseler A,Iwakawa R,et al.Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.Cancer Genet2013;206:73-80.
[114]Leary RJ,Sausen M,Kinde I,Papadopoulos N,Carpten JD,Craig D,et al.Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.Sci Transl Med 2012;4:162ra54.
[115]Narayan A,Carriero NJ,Gettinger SN,Kluytenaar J,Kozak KR,Yock TI,et al.Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.Cancer Res 2012;72:3492-8.
[116]Vinayanuwattikun C,Sriuranpong V,Tanasanvimon S,Chantranuwat P,Mutirangura A.Epithelial-specific methylation marker:a potential plasma biomarker in advanced non-small cell lung cancer.J Thorac Oncol 2011;6:1818-25.
[117]Jiao L,Zhu J,Hassan MM,Evans DB,Abbruzzese JL,Li D.K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients:in relation to cigarette smoking.Pancreas 2007;34:55-62.
[118]He WS,Bishop KS.The potential use of cell-free-circulatingtumor DNA as a biomarker for prostate cancer.Expert Rev Mol Diagn 2016;16:839-52.
[119]Cherepanova AV,Tamkovich SN,Bryzgunova OE,Vlassov VV,Laktionov PP.Deoxyribonuclease activity and circulating DNAconcentration in blood plasma of patients with prostate tumors.Ann NY Acad Sci 2008;1137:218-21.
[120]Delgado PO,Alves BC,Gehrke Fde S,Kuniyoshi RK,Wroclavski ML,Del Giglio A,et al.Characterization of cellfree circulating DNA in plasma in patients with prostate cancer.Tumour Biol 2013;34:983-6.
[121]Kinde I,Bettegowda C,Wang Y,Wu J,Agrawal N,Shih Ie M,et al.Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.Sci Transl Med 2013;5:167ra4.
[122]Murtaza M,Dawson SJ,Tsui DW,Gale D,Forshew T,Piskorz AM,et al.Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.Nature 2013;497:108-12.
[123]Sikora K,Bedin C,Vicentini C,Malpeli G,D’Angelo E,Sperandio N,et al.Evaluation of cell-free DNA as a biomarker for pancreatic malignancies.Int J Biol Markers 2015;30:e136-41.
[124]Laird PW.The power and the promise of DNA methylation markers.Nat Rev Cancer 2003;3:253-66.
[125]Feinberg A.DNA methylation in cancer:three decades of discovery.Genome Med 2014;6:1-4.
[126]Jin H,Ma Y,Shen Q,Wang X.Circulating methylated DNA as biomarkers for cancer detection.methylation-from DNA,RNAand histones to diseases and treatment.Intech 2013:137-52.
[127]Miotto E,Sabbioni S,Veronese A,Calin GA,Gullini S,Liboni A,et al.Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.Cancer Res2004;64:8156-9.
[128]Grady WM,Rajput A,Lutterbaugh JD,Markowitz SD.Detection of aberrantly methylated h MLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.Cancer Res 2001;61:900-2.
[129]Zou HZ,Yu BM,Wang ZW,Sun JY,Cai H,Gao F,et al.Detection of aberrant p16 methylation in the serum of colorectal cancer patients.Clin Cancer Res 2002;8:188-91.
[130]Lecomte T,Berger A,Zinzindohoue F,Micard S,Landi B,Blons H,et al.Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.Int J Cancer 2002;100:542-8.
[131]Ebert MP,Model F,Mooney S,Hale K,Lograsso J,TonnesPriddy L,et al.Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.Gastroenterology 2006;131:1418-30.
[132]Lofton-Day C,Model F,Devos T,Tetzner R,Distler J,Schuster M,et al.DNA methylation biomarkers for blood-based colorectal cancer screening.Clin Chem 2008;54:414-23.
[133]Warren JD,Xiong W,Bunker AM,Vaughn CP,Furtado LV,Roberts WL,et al.Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.BMC Med 2011;9:133.
[134]De Vos T,Tetzner R,Model F,Weiss G,Schuster M,Distler J,et al.Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.Clin Chem 2009;55:1337-46.
[135]Silva J,Dominguez G,Gonzalez R,Garcia J,Corbacho C,Provencio M,et al.Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients.Br JCancer 1999;80:1262-4.
[136]Esteller M,Sanchez-Cespedes M,Rosell R,Sidransky D,Baylin SB,Herman JG.Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.Cancer Res 1999;59:67-70.
[137]El Messaoudi S,Rolet F,Mouliere F,Thierry AR.Circulating cell free DNA:preanalytical considerations.Clin Chim Acta2013;424:222-30.
[138]Wang WY,Barratt BJ,Clayton DG,Todd JA.Genome-wide association studies:theoretical and practical concerns.Nat Rev Genet 2005;6:109-18.
[139]Xu J,Mo Z,Ye D,Wang M,Liu F,Jin G,et al.Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4.Nat Genet2012;44:1231-5.
[140]Forshew T,Murtaza M,Parkinson C,Gale D,Tsui DWY,Kaper F,et al.Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.Sci Transl Med 2012;4:136ra68.
[141]Ashida A,Sakaizawa K,Mikoshiba A,Uhara H,Okuyama R.Quantitative analysis of the BRAF mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific Taq Man PCR.Int J Clin Oncol 2016;21:981-8.
[142]Hindson CM,Chevillet JR,Briggs HA,Gallichotte EN,Ruf IK,Hindson BJ,et al.Absolute quantification by droplet digital PCR versus analog real-time PCR.Nat Methods2013;10:1003-5.
[143]Newman AM,Bratman SV,To J,Wynne JF,Eclov NC,Modlin LA,et al.An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.Nat Med2014;20:548-54.
[144]Bratman SV,Newman AM,Alizadeh AA,Diehn M.Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.Expert Rev Mol Diagn 2015;15:715-9.
[145]Newman AM,Lovejoy AF,Klass DM,Kurtz DM,Chabon JJ,Scherer F,et al.Integrated digital error suppression for improved detection of circulating tumor DNA.Nat Biotechnol2016;34:547-55.
[146]Chan KC,Jiang P,Zheng YW,Liao GJ,Sun H,Wong J,et al.Cancer genome scanning in plasma:detection of tumor-associated copy number aberrations,single-nucleotide variants,and tumoral heterogeneity by massively parallel sequencing.Clin Chem 2013;59:211-24.
[147]Vogelstein B,Kinzler KW.Digital PCR.Proc Natl Acad Sci U S A1999;96:9236-41.
[148]Gray ES,Rizos H,Reid AL,Boyd SC,Pereira MR,Lo J,et al.Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.Oncotarget 2015;6:42008-18.
[149]Tsao SC,Weiss J,Hudson C,Christophi C,Cebon J,Behren A,et al.Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Sci Rep 2015;5:11198.
[150]Huang A,Zhang X,Zhou SL,Cao Y,Huang XW,Fan J,et al.Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity.J Cancer 2016;7:1907-14.
[151]Laurent-Puig P,Pekin D,Normand C,Kotsopoulos SK,Nizard P,Perez-Toralla K,et al.Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.Clin Cancer Res 2015;21:1087-97.
[152]Denis JA,Patroni A,Guillerm E,Pe′pin D,Benali-Furet N,Wechsler J,et al.Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.Mol Oncol 2016;10:1221-31.
[153]Mishima C,Kagara N,Matsui S,Tanei T,Naoi Y,Shimoda M,et al.Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients.Springerplus2015;4:635.
[154]Balgkouranidou I,Chimonidou M,Milaki G,Tsaroucha E,Kakolyris S,Georgoulias V,et al.SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.Clin Chem Lab Med 2016;54:1385-93.
[155]Wang J,Qin Y,Li B,Sun Z,Yang B.Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.Clin Biochem 2006;39:344-8.
[156]Feehery GR,Pradhan S.Method for enriching methylated Cp Gsequences.US Patent Application 2013;US8367331.
[157]Herman JG,Graff JR,Myo¨ha¨nen S,Nelkin BD,Baylin SB.Methylation-specific PCR:a novel PCR assay for methylation status of Cp G islands.Proc Natl Acad Sci U S A 1996;93:9821-6.
[158]Licchesi JD,Herman JG.Methylation-specific PCR.Methods Mol Biol 2009;507:305-23.
[159]Kimler B,Fackler MJ,Metheny T,Phillips T,Sukumar S,Fabian C.Consistency of quantitative multiplexed-methylation specific PCR(QM-MSP)performed on breast epithelial cells acquired by random periareolar fine needle aspiration(RPFNA)of women at high risk for development of breast cancer.Cancer Res 2007;67.
[160]Bailey VJ,Zhang Y,Keeley BP,Yin C,Pelosky KL,Brock M,et al.Single-tube analysis of DNA methylation with silica superparamagnetic beads.Clin Chem 2010;56:1022-5.
[161]Wong IH,Lo YM,Zhang J,Liew CT,Ng MH,Wong N,et al.Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.Cancer Res 1999;59:71-3.
[162]Eads CA,Danenberg KD,Kawakami K,Saltz LB,Blake C,Shibata D,et al.Methy Light:a high-throughput assay to measure DNA methylation.Nucl Acids Res 2000;28:E32.
[163]Bailey VJ,Keeley BP,Zhang Y,Ho YP,Easwaran H,Brock MV,et al.Enzymatic incorporation of multiple dyes for increased sensitivity in QD-FRET sensing for DNA methylation detection.Chem Bio Chem 2010;11:71-4.
[164]Guzzetta AA,Pisanic Ii TR,Sharma P,Yi JM,Stark A,Wang TH,et al.The promise of methylation on beads for cancer detection and treatment.Expert Rev Mol Diagn 2014;14:845-52.
[165]Fackler MJ,Lopez Bujanda Z,Umbricht C,Teo WW,Cho S,Zhang Z,et al.Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.Cancer Res 2014;74:2160-70.
[166]Li Y,Zhu J,Geng T,Ning L,Li Q,Ye M,et al.The DNAmethylome of human peripheral blood mononuclear cells.PLo SBiol 2010;8:549-52.
[167]Urich MA,Nery JR,Lister R,Schmitz RJ,Ecker JR.Methyl C-seq library preparation for base-resolution whole-genome bisulfite sequencing.Nat Protoc 2015;10:475-83.
[168]Smith ZD,Gu HC,Bock C,Gnirke A,Meissner A.Highthroughput bisulfite sequencing in mammalian genomes.Methods 2009;48:226-32.
[169]Serre D,Lee BH,Ting AH.MBD-isolated genome sequencing provides a high-throughput and comprehensive survey of DNAmethylation in the human genome.Nucl Acids Res2010;38:391-9.
[170]Clark C,Palta P,Joyce CJ,Scott C,Grundberg E,Deloukas P,et al.A comparison of the whole genome approach of Me DIP-Seq to the targeted approach of the infinium humanmethylation450 Bead Chipòfor methylome profiling.PLo S One 2012;7:e50233.
[171]Taiwo O,Wilson GA,Morris T,Seisenberger S,Reik W,Pearce D,et al.Methylome analysis using Me DIP-seq with low DNAconcentrations.Nat Protoc 2012;7:617-36.
[172]Chan KC,Jiang P,Chan CW,Sun K,Wong J,Hui EP,et al.Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing.Proc Natl Acad Sci U S A2013;110:18761-8.
[173]Wen L,Li J,Guo H,Liu X,Zheng S,Zhang D,et al.Genomescale detection of hypermethylated Cp G islands in circulating cell-free DNA of hepatocellular carcinoma patients.Cell Res2015;25:1250-64.
[174]Rand K,Qu W,Ho T,Clark SJ,Molloy P.Conversion-specific detection of DNA methylation using real-time polymerase chain reaction(Con Light-MSP)to avoid false positives.Methods2002;27:114-20.
[175]Ilie M,Hofman V,Long E,Bordone O,Selva E,Washetine K,et al.Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids,and their characterization in non-small cell lung carcinoma patients.What is the best blood substrate for personalized medicine?Ann Transl Med2014;2:107.
[176]Gormally E,Caboux E,Vineis P,Hainaut P.Circulating free DNA in plasma or serum as biomarker of carcinogenesis:practical aspects and biological significance.Mutat Res2007;635:105-17.
[177]Schwarzenbach H,Muller V,Milde-Langosch K,Steinbach B,Pantel K.Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease.Mol Biosyst 2011;7:2848-54.
[178]Park JL,Kim HJ,Choi BY,Lee HC,Jang HR,Song KS,et al.Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients.Oncol Lett 2012;3:921-6.
[179]Salvianti F,Pinzani P,Verderio P,Ciniselli CM,Massi D,De Giorgi V,et al.Multiparametric analysis of cell-free DNA in melanoma patients.PLo S One 2012;7:e49843.
[180]Ha TT,Huy NT,Murao LA,Lan NT,Thuy TT,Tuan HM,et al.Elevated levels of cell-free circulating DNA in patients with acute dengue virus infection.PLo S One 2011;6:e25969.
[181]Huang CH,Tsai MS,Hsu CY,Chen HW,Wang TD,Chang WT,et al.Circulating cell-free DNA levels correlate with postresuscitation survival rates in out-of-hospital cardiac arrest patients.Resuscitation 2012;83:213-8.
[182]Iriyama C,Tomita A,Hoshino H,Adachi-Shirahata M,Furukawa-Hibi Y,Yamada K,et al.Using peripheral blood circulating DNAs to detect Cp G global methylation status and genetic mutations in patients with myelodysplastic syndrome.Biochem Biophys Res Commun 2012;419:662-9.
[183]Kwee S,Song MA,Cheng I,Loo L,Tiirikainen M.Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer.Clin Transl Sci 2012;5:65-70.
[184]Klein CA.Parallel progression of primary tumours and metastases.Nat Rev Cancer 2009;9:302-12.
[185]Ma M,Zhu H,Zhang C,Sun X,Gao X,Chen G.‘‘Liquid biopsy”-ct DNA detection with great potential and challenges.Ann Transl Med 2015;3:235.
[186]Pan H,Chen L,Dogra S,Teh AL,Tan JH,Lim YI,et al.Measuring the methylome in clinical samples:improved processing of the infinium human methylation450 beadchip array.Epigenetics 2012;7:1173-87.
[187]Mack SC,Witt H,Piro RM,Gu L,Zuyderduyn S,Stutz AM,et al.Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.Nature 2014;506:445-50.
[188]Hudecova I.Digital PCR analysis of circulating nucleic acids.Clin Biochem 2015;48:948-56.
[189]Jansen M,Martens J,Helmijr J,Beaufort C,Van M,Krol N,et al.Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.Oncotarget 2016;7:43412-8.
[190]Souverijn JH.Multitarget stool DNA testing for colorectalcancer screening.N Engl J Med 2014;371:187.
[191]Church TR,Wandell M,Lofton-Day C,Mongin SJ,Burger M,Payne SR,et al.Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.Gut2014;63:317-25.
[192]Ilse P,Biesterfeld S,Pomjanski N,Wrobel C,Schramm M.Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.Cancer Genomics Proteomics 2014;11:251-8.
[193]Brown P.The Cobas(ò)EGFR mutation test v2 assay.Future Oncol 2016;12:451-2.
[194]Kopreski M,Benko F,Kwee C,Leitzel K,Eskander E,Lipton A,et al.Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.Br J Cancer 1997;76:1293.
[195]Yamada T,Nakamori S,Ohzato H,Oshima S,Aoki T,Higaki N,et al.Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma:correlation with clinicopathological features.Clin Cancer Res 1998;4:1527-32.
[196]Sanchez-Cespedes M,Monzo M,Rosell R,Pifarre A,Calvo R,Lopez-Cabrerizo MP,et al.Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients.Ann Oncol 1998;9:113-6.